Oxidised LDL modulates immune-activation by an IL-12 dependent mechanism

Atherosclerosis

Volumn 169, Issue 1, 2003, Pages 77-85

  Fei, Guo Zhong ^a   Huang, Yi Hui ^a   Swedenborg, Jesper ^a   Frostegård, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Cytokines; Lymphocytes; Oxidised low density lipoprotein

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOREACTIVITY; IMMUNOSTIMULATION; MOLECULAR MIMICRY; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH2 CELL;

EID: 0038306213     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00146-1     Document Type: Article

References (38)

1. Hansson G.K., Holm J., Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 135:1989;169-175.
2. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
3. Xu Q., Dietrich H., Steiner H.J., et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12:1992;789-799.
4. Frostegard J., Wu R., Giscombe R., Holm G., Lefvert A.K., Nilsson J. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler. Thromb. 12:1992;461-467.
5. Cook P.J., Lip G.Y. Infectious agents and atherosclerotic vascular disease. Q. J. Med. 89:1996;727-735.
6. Witztum J.L. The oxidation hypothesis of atherosclerosis [see comments]. Lancet. 344:1994;793-795.
7. Quinn M.T., Parthasarathy S., Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. USA. 85:1988;2805-2809.
8. Frostegard J., Nilsson J., Haegerstrand A., Hamsten A., Wigzell H., Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc. Natl. Acad. Sci. USA. 87:1990;904-908.
9. Berliner J.A., Territo M.C., Sevanian A., et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 85:1990;1260-1266.
10. Uyemura K., Demer L.L., Castle S.C., et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest. 97:1996;2130-2138.
11. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA. 92:1995;3893-3897.
12. Frostegard J., Huang Y.H., Ronnelid J., Schafer-Elinder L. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler. Thromb. Vasc. Biol. 17:1997;963-968.
13. Huang Y.H., Schafer-Elinder L., Wu R., Claesson H.E., Frostegard J. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin. Exp. Immunol. 116:1999;326-331.
14. Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 341:1993;923-925.
15. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145:1997;408-415.
16. Svenungsson E., Jensen-Urstad K., Heimbürger M., et al. Risk factors for arterial disease in systemic lupus erythematosus. Circulation. 104:2001;1887-1893.
17. Horkko S., Miller E., Dudl E., et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J. Clin. Invest. 98:1996;815-825.
18. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol. 15:1995;1512-1531.
19. Huang Y.H., Ronnelid J., Frostegard J. Oxidized LDL induces enhanced antibody formation and MHC class II-dependent IFN-gamma production in lymphocytes from healthy individuals. Arterioscler. Thromb. Vasc. Biol. 15:1995;1577-1583.
20. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1955;1345-1353.
21. Lowry O., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
22. Asaoka Y., Oka M., Yoshida K., Sasaki Y., Nishizuka Y. Role of lysophosphatidylcholine in T-lymphocyte activation: involvement of phospholipase A2 in signal transduction through protein kinase C. Proc. Natl. Acad. Sci. USA. 89:1992;6447-6451.
23. Asaoka Y., Oka M., Yoshida K., Nishizuka Y. Lysophosphatidylcholine as a possible second messenger synergistic to diacylglycerol and calcium ion for T-lymphocyte activation. Biochem. Biophys. Res. Commun. 178:1991;1378-1385.
24. Nishi E., Kume N., Ueno Y., Ochi H., Moriwaki H., Kita T. Lysophosphatidylcholine enhances cytokine-induced interferon gamma expression in human T lymphocytes. Circ. Res. 83:1998;508-515.
25. Sakata-Kaneko S., Wakatsuki Y., Usui T., et al. Lysophosphatidylcholine upregulates CD40 ligand expression in newly activated human CD4+ T cells. FEBS. Lett. 433:1998;161-165.
26. Kouwenhoven M., Ozenci V., Teleshova N., Hussein Y., Huang Y.M., Eusebio A., Link H. Enzyme-linked immunospot assays provide a sensitive tool for detection of cytokine secretion by monocytes. Clin. Diagn. Lab. Immunol. 8:2001;1248-1257.
27. Caspar-Bauguil S., Saadawi M., Negre-Salvayre A., Thomsen M., Salvayre R., Benoist H. Mildly oxidized low-density lipoproteins suppress the proliferation of activated CD4+ T-lymphocytes and their interleukin 2 receptor expression in vitro. Biochem. J. 330:(Pt.2):1998;659-666.
28. Wu R., Huang Y.H., Elinder L.S., Frostegard J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 18:1998;626-630.
29. Wu R., Lemne C., De Faire U., Frostegard J. Antibodies to platelet-activating factor are associated with borderline hypertension, early atherosclerosis and the metabolic syndrome. J. Intern. Med. 246:1999;389-397.
30. Palinski W., Miller E., Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA. 92:1995;821-825.
31. Freigang S., Horkko S., Miller E., Witztum J.L., Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18:1998;1972-1982.
32. Wu R., de Faire U., Lemne C., Witztum J.L., Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension. 33:1999;53-59.
33. Hulthe J., Wiklund O., Hurt-Camejo E., Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler. Thromb. Vasc. Biol. 21:2001;269-274.
34. Frostegard J., Kjellman B., Gidlund M., Andersson B., Jindal S., Kiessling R. Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis. 121:1996;93-103.
35. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N., Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science. 293:2001;702-705.
36. Wuttge D.M., Bruzelius M., Stemme S. T-cell recognition of lipid peroxidation products breaks tolerance to self proteins. Immunology. 98:1999;273-279.
37. Horkko S., Miller E., Branch D.W., Palinski W., Witztum J.L. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc. Natl. Acad. Sci. USA. 94:1997;10356-10361.
38. Elinder L.S., Dumitrescu A., Larsson P., Hedin U., Frostegard J., Claesson H.E. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler. Thromb. Vasc. Biol. 17:1997;2257-2263.